NCT03215264View on ClinicalTrials.gov

To Determine the Safety of Regorafenib, Hydroxychloroquine, and Entinostat Metastatic Colorectal Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

October 2, 2017

Primary Completion Date

June 1, 2020

Study Completion Date

June 1, 2020

Conditions
Colorectal Cancer
Interventions
DRUG

hydroxychloroquine

600-1200mg daily

DRUG

entinostat

3-5mg weekly

DRUG

regorafenib

160mg daily

Trial Locations (1)

19104

Abramson Cancer Center of the University of Pennsylvania, Philadelphia

All Listed Sponsors
lead

Abramson Cancer Center at Penn Medicine

OTHER

NCT03215264 - To Determine the Safety of Regorafenib, Hydroxychloroquine, and Entinostat Metastatic Colorectal Cancer | Biotech Hunter | Biotech Hunter